Agenus | AGEN - Assets


Agenus reported $172.69M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Agenus USD 172.69M 13.76M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Celldex Therapeutics USD 782.35M 271.09M Jun/2026
CSL USD 37.9B 1.5B Dec/2025
Eli Lilly USD 142.28B 25.71B Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Glaxosmithkline GBP 62.87B 19.47B Mar/2026
Incyte USD 7.87B 533.53M Jun/2026
Intrexon USD 73.16M 77.88M Jun/2024
J&J USD 201.06B 167M Jun/2026
Jiangsu Hengrui CNY 70.77B 520.74M Jun/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
MacroGenics USD 345.41M 127.54M Jun/2026
Merck EUR 52.69B 383M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Northwest Biotherapeutics USD 80.05M 49.44M Mar/2026
Novartis USD 122.03B 3.5B Jun/2026
Novavax USD 955.58M 87.59M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Veracyte USD 1.49B 49.97M Jun/2026